scorecardresearch
Thursday, April 25, 2024
TopicCovaxin

Topic: Covaxin

‘Fake news’ — Bharat Biotech, govt deny report on ‘discrepancies’ in Covaxin trial data

Medical news site STAT had cited internal documents to allege that Bharat Biotech had taken ‘questionable’ steps under political pressure to speed up development of Covaxin.

Covaxin safe for kids, generates higher antibody response in them than adults, says Lancet paper

The results of the phase ⅔ clinical trials of the indigenous Covid vaccine have been peer-reviewed and published in the The Lancet Infectious Diseases journal.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

As booster uptake lags in pvt sector, officials say health system can’t be in Covid mode forever

Third Covid vaccine dose available only in pvt hospitals. Health officials say routine procedures need to be brought back on track, but govt hospitals could be brought in if needed.

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

Covaxin to be evaluated as Covid-19 vaccine candidate in US as FDA lifts clinical hold

As many as 110 countries have agreed to mutual recognition of Covid-19 vaccination certificates with India that includes vaccination using Covaxin.

Covaxin supplies, trial group size — why there’s a delay in Covid vaccine for younger kids

Monthly Covaxin output between 5.5-6.5 cr. Country needs at least 15 cr doses for full coverage 15-18 age group. Choice of 6 μg dose reduced manufacturing capacity, says Bharat Biotech.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

Why you won’t get Covishield, Covaxin at a chemist yet, despite full market approval

Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.

DCGI grants regular market approval to Covishield, Covaxin for use in adult population

Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.

On Camera

Imtiaz Ali obsesses over vulgarity, misses Chamkila’s cultural resistance against purity

Peter Manuel's ‘Cassette Culture’ showed the booming Bhakti music during the '80s and '90s when Anoop Jalota, Gulshan Kumar achieved success by singing the sanitised Bhajans.

Economists vs statisticians — the battle being fought over the soul of India’s GDP data

Economists say there are weaknesses in India’s GDP data. But statisticians claim the accusations are based on flawed understanding, saying while GDP has problems, the economists are looking in the wrong places.

India and Japan hold 10th round of consultations on disarmament, non-proliferation, and export control

The two sides also discussed ways to strengthen cooperation in outer space security, conventional weapons, and export control

These 6 states are key for Modi’s ‘400 paar’ target. They’re also where Opposition can stop him

While this contest looks so predictable in large swathes of our political landscape, it is also more keenly contested than 2019 in some states.